# FundaMental Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fundamental-pharma

- Industry: Biotechnology
- Headquarters: Heidelberg, Germany
- Website: https://fundamentalpharma.com/
- Total disclosed funding: $9.8M
- Latest round: Seed (Sep 30, 2022)
- Investors on record: 4

## About

Based in Germany, FundaMental Pharma GmbH specializes in developing innovative therapeutic solutions targeting neurodegenerative disorders, focusing on advanced treatments to enhance neuronal survival and cognitive function.Founded in 2016 and headquartered in Heidelberg, Germany, FundaMental Pharma GmbH is engaged in the research and development of therapies for neurodegenerative diseases. The company has successfully completed 2 deals, with the most recent funding occurring on September 30, 2022, where the firm raised EUR 10 million in a Seed round led by BioGeneration Ventures, joined by Coparion, Thuja Capital, and High-Tech Gründerfonds. The company was co-founded by Daniela Mauceri, Hilmar Bading, Jing Yan, and Thomas Schulze, with Thomas Schulze currently serving as the CEO.FundaMental Pharma GmbH specializes in innovative therapeutic solutions aimed at combating neurodegenerative disorders. The company focuses on First-in-Class NMDAR/TRPM4 (N/T) Interface Inhibitors, which target the physiological functions of glutamate-gated NMDA receptors while mitigating their toxic effects associated with neurodegeneration. This mechanism preserves beneficial synaptic NMDA receptor functions on neuronal survival and memory, addressing conditions such as Alzheimer's disease. FundaMental Pharma's products are designed for clinical use, targeting healthcare providers, research institutions, and pharmaceutical partners globally, especially in Europe and North America.FundaMental Pharma generates revenue primarily through partnerships and collaborations with research institutions and pharmaceutical companies engaged in developing its therapeutic solutions. The revenue structure includes licensing agreements, milestone payments, and potential royalties from future sales of its NMDAR/TRPM4 (N/T) Interface Inhibitors, involving upfront payments and subsequent payments linked to specific development or regulatory milestones. The company’s pricing aligns with industry standards for novel biotechnology products, reflecting substantial research and development investments, and predominantly operates in a B2B model with established biopharmaceutical entities.FundaMental Pharma GmbH plans to utilize the EUR 10 million raised in Seed funding to advance the development of a neuroprotectant. The company aims to launch new products targeting neurodegenerative disorders and expand its market reach into additional regions over the next few years, specifically focusing on enhancing its presence in Europe and North America. The funding will support the advancement of clinical trials and further research necessary for bringing its innovative therapeutics to market.

## Funding rounds

- Seed, Sep 30, 2022, $9.8M — BioGeneration Ventures, Thuja Capital, High-Tech Gruenderfonds, Coparion
- Seed, Jun 23, 2021 — High-Tech Gruenderfonds

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Seed
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Seed
- Coparion (https://capitalatlas.ai/funds/coparion) — Seed